Artikler: 7000  * Produkter: 677   Kurguider: 246    ·  Home  ·  Sitemap  ·  Links     
   
    FORSIDE  |  HELSE NYT  |  GENVEJ TIL LIVET  |  GENVEJ TIL SYGDOM  |  GUIDER  |  BASISBLADE  |  PRODUKTER  |  KURGUIDEN  |  OPSKRIFTER  

  Artikler & Produktviden
  Produktfakta
  
 
Send denne side til en som det kan gavne Udskriv siden

De videnskabelige beviser for Alfa-liponsyre

Perifer diabetisk neuropati
Den gavnlige effekt af oral Alfa-liponsyre blev påvist i et forsøg offentliggjort i 2006. I dette dobbeltblind, placebo-kontrollerede forsøg fik 181 personer med perifer diabetisk neuropati enten placebo eller 600, l.200 eller l.800 mg Alfa-liponsyre dagligt. I løbet af de fem uger, forsøget varede, kunne man påvise en gavnlig effekt i alle tre Alfa-liponsyre-grupper sammenlignet med placebo-gruppen.

Ud over dette forsøg er de positive beviser for oral Alfa-liponsyre mod perifer diabetisk neuropati begrænset til åbne forsøg uden nævneværdig gyldighed og dobbeltblind forsøg, der er for små til at være troværdige. Foreløbige beviser tyder på, at Alfa-liponsyre fungerer bedre, hvis det kombineres med gamma-linolensyre (GLA), et andet tilskud, der anvendes mod perifer diabetisk neuropati.

Autonom neuropati
Beviserne er bedre for oralt indgivet Alfa-liponsyre mod den form for diabetisk neuropati, der påvirker de nerver, der forsyner hjertet: autonom neuropati. Diabetes beskadiger ikke blot nerver i arme og ben, men kan også påvirke de dybtliggende nerver, der kontroller organer som hjerte og fordøjelseskanal. Det såkaldte Deutsche Kardiale Autonome Neuropathie (DEKAN) forsøg fulgte 73 diabetikere med symptomer fra nerveskader, der påvirker hjertet. Behandling med 800 mg oral Alfa-liponsyre dagligt viste en signifikant forbedring i forhold til placebo og gav stort set ingen bivirkninger.

Brændende mund-syndrom (BMS)
Brændende mund-syndrom giver en fornemmelse af at blive skoldet i munden, som om man har drukket noget meget varmt. Årsagen til BMS er ikke kendt, men symptomerne ligner dem, der ses ved neuropati, og derfor har man undersøgt det sundhedsfremmende potentiale ved Alfa-liponsyre.

I et to måneder langt, dobbelt-blind forsøg med 60 BMS-patienter var Alfa-liponsyre i stand til i signifikant grad at reducere symptomerne i forhold til placebo. Men tre små dobbeltblind forsøg viste ikke nogen sundhedsfremmende egenskaber ved Alfa-liponsyre.

Sikkerhedsspørgsmål
Alfa-liponsyre synes ikke at have bivirkninger i doser på op til l.800 mg dagligt. Man har ikke fastlagt sikkerheden for børn, gravide, ammende eller personer med alvorlig lever- eller nyresygdom.

Referencer:
Kagan VE, Shvedova A, Serbinova E, et al. Dihydrolipoic acid - a universal antioxidant both in the membrane and in the aqueous phase. Reduction of peroxyl, ascorbyl, and chromanoxyl radicals. Biochem Pharmacol. 1992;44:1637-1649.
Matsugo S, Yan LJ, Han D, et al. Elucidation of antioxidant activity of alpha-lipoic acid toward hydroxyl radical. Biochem Biophys Res Commun, 1995;208:161-167.
Pac ker L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995;19:227-250.
Podda M, Tritschler HJ, Ulrich H, et al. Alpha-lipoic acid supplementation prevents symptoms of vitamin E deficiency. Biochem Biophys Res Commun. 1994;204:98-104,
Ziegler D, Hanefeld M, Ruhnau KJ, et al. The ALADIN III Study Group. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). Diabetes Care. 1999;22:1296-1301. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38:1425-1433.
Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes. 1997;46(suppl 2):S62-S66.
Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes. 1997;46(suppl 2):S62-S66.
Jacob S, Henriksen EJ, Schiemann AL, et al. Enhancement of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid. Arzneimittelforschung. 1995;45:872-874.
Kawabata T, Packer L. Alpha-lipoate can protect against glycation of serum albumin, but not low density lipoprotein. Biochem Biophys Res Commun. 1994;203:99-104.
Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care. 1995;18:1160-1167.
Suzuki YJ, Tsuchiya M, Packer L. Lipoate prevents glucose-induced protein modifications. Free Radic Res Commun. 1992; 17:211-217.
Jacob S. Ruus P, Hermann R, et al. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med. 1999;27:309-314.
Seidman MD, Khan MJ, Bai U, et al. Biologic activity of mitochondrial metabolites on aging and age-related hearing loss. Am J Otol. 2000;21:161-167.
Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Diabetes Care. 1999;22:1296-1301.
Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38:1425-1433.
Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes. 1997;46(suppl 2):S62-S66.
Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes. 1997;46(suppl 2):S62-S66.
Kahler W, Kuklinski B, Ruhlmann C, et al. Diabetes mellitus - a free radical-associated disease. Results of adjuvant antioxidant supplementation [in German; English abstract]. Z Gesamte Inn Med. 1993;48:223-232.
Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38:1425-1433.
Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995;19:227-250.
Ruhnau KJ, Meissnert HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999;16:1040-1043.
Hounsom L, Horrobin DF, Tritschler H et al. A lipoic acid-gamma linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropathy. Diabetologia. 1998;41:839-843. Cameron NE, Cotter MA, Horrobin DH, et al. Effects of alpha-lipoic acid on neurovascular function in diabetic rats: Interaction with essential fatty acids. Diabetologia. 1998;41:390-399.
Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes. 1997;46(suppl 2):S62-S66.
Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Diabetes Care. 1999;22:1296-1301.
Dincer Y, Telci A, Kayali R, Yilmaz IA, et al. Effect Of alpha-Lipoic Acid On Lipid Peroxidation And Anti-Oxidant Enzyme Activities In Diabetic Rats. Clin Exp Pharma Physiol 2002;29:281-284. Melhem MF, Graven PA, Liachenko J, et al. Alpha-lipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes. J Am Soc Nephrol. 2002;13:108-116. Femiano F, Scully C. Burning mouth syndrome (BMS): double blind controlled study of alpha-lipoic acid (thioctic acid) therapy. J Oral Pathol Med. 2002;31:267-269.
Filina AA, Davydova NG, Endrikhovskii SN, et al. Lipoic acid as a means of metabolic therapy of open-angle glaucoma. Vestn Oftalmol. 1995;111:6-8.
Beitner H. Randomized, placebo-controlled, double blind study on the clinical efficacy of a cream containing 5 % alpha-lipoic acid related to photoageing of facial skin. Br J Dermatol. 2003;149:841-849.
Ziegler D. Ametov A, Barinov A, et al. Oral Treatment With Alpha-Lipoic Acid Improves Symp­tomatic Diabetic Polyneuropathy: The SYDNEY 2 trial. Diabetes Care. 2006;29:2365-2370. Balachandar AV, Malarkodi KP, Varalakshmi P. Protective role of DL alpha-lipoic acid against adriamycin-induced cardiac lipid peroxidation. Hum Exp Toxicol. 2003;22:249-254.
Al-Majed AA, Gdo AM, Al-Shabanah OA, et al. Alpha-lipoic acid ameliorates myocardial toxicity induced by doxorubicm.-Pharmacol Res. 2002;46:499-503.
Magis D, Ambrosini A, Sandor P, et al. A randomized, double-blind, placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache. 2007;47:52-57.
Carbone M, Pentenero M, Carrozzo M, et al. Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: A double-blind, randomized, placebo-controlled study. Eur J Pain. 2008 Jul 31.
Lopez-Jornet P, Camacho-Alonso F, Leon-Espinosa S. Efficacy of alpha lipoic acid in burning mouth syndrome: a randomized, placebo-treatment study. J Oral Rehabil. 2008 Oct 18.
Cavalcanti DR, da Silveira FR. Alpha lipoic acid in burning mouth syndrome - a randomized double-blind placebo-controlled trial. J Oral Pathol Med. 2009;38:254-61.

Health Library - C573 - Lipoic Acid - Natural, Alternative - 21480

Føres eller fremskaffes af dit nærmeste apotek, Matas eller helsekostforretning, der er godkendt til forhandling af håndkøbsmedicin.

Kilde: Hus & Haveavisen nr. 8, 2012, s. 52: http://www.husoghaveavisen.dk/

Yderligere oplysninger på
http://www.diabetes.dk/
http://www.scleroseforeningen.dk/
http://www.netdoktor.dk/
http://www.wikipedia.org/

Health News 2012

 

 

Forrige sideGå til toppen af siden
Powered by SiteManager © 2002-2012